Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU.

Zhao, Hailin; Davies, Roger; Ma, Daqing

Zhao, Hailin; Davies, Roger; Ma, Daqing.

Zhao H; Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Davies R; Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Magill Department of Anaesthetics, Chelsea and Westminster Hospital Foundation Trust, London, UK.
Ma D; Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. Electronic address: d.ma@imperial.ac.uk.

Br J Anaesth ; 126(1): e33-e35, 2021 01.

Article in English | MEDLINE | ID: covidwho-813489

Subject(s)

Adrenergic alpha-2 Receptor Agonists/therapeutic use; COVID-19 Drug Treatment; Dexmedetomidine/therapeutic use; Intensive Care Units/trends; Patient Admission/trends; COVID-19/blood; COVID-19/immunology; Cytokine Release Syndrome/blood; Cytokine Release Syndrome/drug therapy; Cytokine Release Syndrome/immunology; Female; Humans; Hypoxia/blood; Hypoxia/drug therapy; Hypoxia/immunology; Male

Keywords

COVID-19; SARS-CoV-2; critical care; dexmedetomidine; multi-organ dysfunction

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Admission / Dexmedetomidine / Adrenergic alpha-2 Receptor Agonists / COVID-19 Drug Treatment / Intensive Care Units Limits: Female / Humans / Male Language: English Journal: Br J Anaesth Year: 2021 Document Type: Article Affiliation country: J.bja.2020.09.031

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google